|
 |
Nekomercijalni |
|
|
Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima
|
|
Humalog |
Argentina, Australija, Austrija, Belgija, Brazil, Čile, Danska, Ekvador, Finska, Francuska, Grčka, Hrvatska, Irska, Island, Italija, Japan, Južna Afrika, Kanada, Kolumbija, Luksemburg, Madžarska, Malezija, Maroko, Meksiko, Nizozemska, Njemačka, Norveška, novi Zeland, Peru, Poljska, Portugal, Rumunjska, S A D, Saudijska Arabija, Slovenija, Španjolska, Švedska, Švicarska, Turska, Ujedinjeni Arapski Emirati, Velika Britanija, Venecuela |
|
|
 |
 |
Bibliografija : Insulin lyspro |
|
|
Vrsta |
Publikacija |
| 2269 |
Časopis |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3149 |
Časopis |
DeFelippis MR, Bell MA, Heyob JA, Storms SM.
In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion.
Diabetes Tech and Ther 2006 ; 8, 3: 358-368. |
| 3249 |
Časopis |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 4433 |
Časopis |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4650 |
Laboratorija |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 5045 |
Laboratorija |
Humalog 100 UI/ml, solution injectable en flacon - Résumé des caractéristiques du produit.
Eli Lilly 2006 |
|
|
